Apellis Fundamentals

APLS
 Stock
  

USD 49.47  0.46  0.92%   

Apellis Pharmaceuticals fundamentals help investors to digest information that contributes to Apellis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Apellis Stock. The fundamental analysis module provides a way to measure Apellis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apellis Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Apellis Pharmaceuticals Operating Expenses is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Operating Expenses of 602.64 Million. As of 12/01/2022, Research and Development Expense is likely to grow to about 373.2 M, while Earning Before Interest and Taxes EBIT is likely to drop (752 M).

Apellis Target Price Analysis

Current Apellis Pharmaceuticals Target Price

    
  74.24  
Most of Apellis Pharmaceuticals' fundamental indicators, such as Target Price, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Compare to competition

Apellis Price to Book Value

Price to Book Value

23.79

Apellis Pharmaceuticals Price to Book Value is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Price to Book Value of 20.78
Based on the latest financial disclosure, Apellis Pharmaceuticals has a Target Price of 74. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The target price for all United States stocks is notably lower than that of the firm.

Apellis Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apellis Pharmaceuticals competition to find correlations between indicators driving Apellis Pharmaceuticals's intrinsic value. More Info.
Apellis Pharmaceuticals is number one stock in z score category among related companies. It is number one stock in working capital category among related companies . Apellis Pharmaceuticals Working Capital is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Working Capital of 692.2 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Apellis Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Apellis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Apellis Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Apellis Pharmaceuticals from analyzing Apellis Pharmaceuticals' financial statements. These drivers represent accounts that assess Apellis Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Apellis Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.31 M)(1.47 M)(1.3 M)(919.6 K)(1.57 M)(1.69 M)
Average Assets104.78 M218.18 M372.66 M821.99 M729.37 M603.86 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(50.88 M)(127.3 M)(304.29 M)(316.62 M)(731.8 M)(751.06 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(50.63 M)(124.99 M)(298.83 M)(312.23 M)(731.27 M)(750.51 M)
Earnings before Tax(51.01 M)(127.5 M)(304.71 M)(343.03 M)(746 M)(765.63 M)
Average Equity86.37 M178.88 M139.41 M200.36 M12.88 M13.21 M
Free Cash Flow(46.6 M)(131.24 M)(212.83 M)(165.91 M)(564.23 M)(579.08 M)
Invested Capital26.32 M37.29 M128.54 M642.93 M318.38 M262.8 M
Invested Capital Average12.63 M31.44 M74.77 M631.45 M556.3 M600.22 M
Tangible Asset Value182.13 M203.53 M389.25 M960.57 M881.76 M951.38 M
Working Capital175.46 M185.41 M307.34 M788.87 M692.2 M546.92 M

Apellis Fundamentals

About Apellis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Cost of Revenue180 K178.9 K
Revenues66.6 M68.3 M
Revenue to Assets 0.08  0.08 
Revenue Per Employee139.8 K143.5 K

Apellis Pharmaceuticals Investors Sentiment

The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.

Pair Trading with Apellis Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Apellis Pharmaceuticals

+0.73LUMNLumen Technologies Upward RallyPairCorr

Moving against Apellis Pharmaceuticals

-0.73RETAReata Pharmaceuticals Normal TradingPairCorr
-0.72JPMJPMorgan Chase Fiscal Year End 13th of January 2023 PairCorr
-0.64RIGTransocean Normal TradingPairCorr
-0.63BACBank Of America Downward RallyPairCorr
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Apellis Pharmaceuticals Piotroski F Score and Apellis Pharmaceuticals Altman Z Score analysis. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.5 B
Quarterly Revenue Growth YOY
2.9
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.